Introduction
The imidazotetrazine prodrug temozolomide 1 (TMZ), a DNA methylating agent, in combination with radiotherapy, is now first line treatment for glioblastoma multiforme (GBM) in North America and Europe.
However, intrinsic and acquired resistance significantly limits the ultimate efficacy of therapy. In particular, tumor re-growth up to two years following TMZ treatment is aggressive and resistant to further TMZ therapy. [1] [2] [3] This paper reports new compounds of the TMZ class that have activity independent of the two principal constraints on the ability of a tumor to respond to TMZ therapy: MGMT activity which directly repairs TMZ GO6-methylation of DNA, and MMR which enables the tumor response to TMZ therapy. 2 Scheme 1. The mechanism of action of temozolomide 1.
At neutral pH, TMZ is relatively unstable (t1/2 = 1.24 h, pH 7.4) 4 
and undergoes hydrolytic ring-cleavage
to the open chain triazene 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC, t1/2 = 8 min, pH 7.4), 5 which then fragments to the highly reactive electrophile, methyldiazonium (t1/2 = 0.39 sec, pH 7.4). [6] [7] [8] Methyldiazonium reacts with nucleophilic groups on DNA, resulting in DNA methylation, Scheme 1.
Approximately 70% of the methyl groups transferred to DNA appear at N7-guanine, 10 % at N3-adenine, and 5 % at O6-guanine sites. The N-methylation products are readily repaired by the base-excision repair pathways so are not major contributors to chemosensitivity. 9 In contrast, O6-MeG lesions are reversed by direct removal by the MGMT protein. The MGMT gene is silenced by promoter methylation in approximately 35% of GBM. 1 In these tumors, persistent O6-MeG lesions form wobble base-pairs with thymidine during replication; O6-MeG=T pairings result in futile cycles of mismatch repair, leading to stalled replication forks, DNA double-strand breaks and ultimately cell death. 1 Low levels of MMR expression (or mutations leading to non-functional MMR) lead to a tolerant phenotype that cannot respond to TMZ. Consistent with these mechanisms of O6-MeG processing and repair, high-level expression of the MGMT protein is a major mechanism of inherent TMZ resistance in primary tumors.
Down regulation or mutations of the MMR pathway or up-regulation of MGMT expression are important causes of acquired TMZ resistance in GBM. 2 Herein we report the synthesis, pre-clinical activity in vitro and QSAR of new imidazotetrazines that have activity independent of MMR and MGMT. To prepare the dimers 3a-f, Cu(I)-catalyzed Aza-Michael conjugate addition of methyl acrylate to the requisite aniline furnished the diesters 8 in good (60-98%) yields, Scheme 4. Conversion to isocyanates 9 was achieved through the intermediate hydrazides 10 and azides 11 followed by Curtius rearrangement.
For the electron rich anilines (X=CH3, OMe), hydrazide formation had to be performed under very mildly acidic (0.17 M AcOH) conditions to avoid nitration of the aniline ring (10e → 11f → 3f). This is an attractive route as the bis-hydrazides are usually solids and easily purified while the Curtius rearrangement produces pure isocyanates directly, free from contaminating by-products.
Scheme 5 Route to mono-imidazotetrazines 2. Reagents and conditions: (i) CuCl, AcOH, Δ, 58-97%; (ii) NH2NH2·xH2O / IPA, Δ, 44-98%; (iii) NaNO2, AcOH, H2O, CH2Cl2, 0 °C; (iv) PhMe, Δ, [>95%]; (v) DMSO, RT, 6-51% over two steps.
The mono-imidazotetrazine analogs 2a-i were similarly prepared from N-methyl anilines, Scheme 5. In one example, the secondary aniline version 2g (R=H, X=Cl) was achieved using a BOC protection strategy that exploited the relative acid stability of the imidazotetrazine ring. Carefully controlled diazotization (12f → 13f → 14f) yielded BOC-protected isocyanatoethylaniline 15f; tetrazine ring closure followed by final treatment with TFA gave secondary aniline 2g. As a similar yield was obtained omitting the BOC group, the protection was shown to be redundant. The p-nitro derivative 2e was accessed from hydrazide 13a by simultaneous diazotization and nitration under more vigorous conditions (10 M HCl) ; the mixture of regioisomers was carried through to the final step where the p-NO2 isomer, tetrazine 2e, was isolated by flash column chromatography. (MMR+) and A2780-cp70 (MMR-) cell lines in the absence (MGMT+) and presence (MGMT-) of the MGMT inactivator PaTrin2 (10 µM). All data are the mean of ≥3 determinations, error bars are the SD; t-test analysis is presented in Table S3 . * IC50 >250 µM. MEL, melphalan; CP, cisplatin.
In vitro QSAR: influence of MGMT and MMR

Screening of all new compounds for chemosensitizing efficacy was undertaken following a protocol by
Margisson et al that used the MGMT and MMR-proficient ovarian carcinoma cell line A2780, and its MMRdeficient derivative A2780-cp70, Figure 1 . 19 To assess dependence of cytotoxicity on MGMT function, each cell line was further treated with the MGMT inactivator PaTrin2. 20 The data are presented graphically in Figure 1 and fully tabulated in Table S1 . As expected, sensitivity to TMZ and mitozolomide (MTZ) was highly dependent on both lack of MGMT activity and presence of wild-type MMR capacity. For TMZ, the IC50 was >250 µM in both A2780 and A2780-Cp70 cell lines, compared with IC50 = 8.5 and 231 µM respectively for the same cell lines co-treated with PaTrin2. In contrast, the novel imidazotetrazines were significantly more potent, with IC50 values in the A2780 wild-type line ranging from 22-73 µM for the mono-functional (2a-i) and 1-15 µM for the bi-functional (3a-f) compounds. Dependence on MMR can be examined by comparing the shaded bars with the grey bars (i.e. MMR+/MMR-with MGMT inactivated in both cases). For temozolomide the IC50 was >27-fold lower in the MMR-proficient cell line. For the new bifunctional agents 3, this ratio was reduced to 5-5.8-fold and for the mono-functional agents 2, 2.8-10-fold.
The extent of MGMT-mediated resistance can be assessed by comparing the shaded and the black bars (i.e.
MGMT-/MGMT+ with MMR competent in both cases). Here, temozolomide was >30-fold more potent when MGMT was inactivated whilst for the new agents, this ratio was 0.5-5-fold for the bi-functional and 1.1-2.9-fold for the mono-functional agents. Importantly, in the absence of MMR, all compounds showed activity greater than temozolomide irrespective of the MGMT status of the cells (white bars and grey bars)
showing that MMR-dependent toxicity and MGMT-mediated resistance are now only minor determinants of the chemosensitizing effect.
The similarity of response of examples 2d and 2g indicate that the N-methyl aniline is not essential to activity as the secondary and tertiary aniline compounds are equipotent (see Figure 1 and Table S1 ).
Retention of the BOC group in analog 2f significantly reduced potency, presumably by impeding the aziridine/aziridinium formation step. Nitration in the aniline ring, whether as the sole or as an additional substituent, resulted in reduced potency. This is consistent with electron withdrawal reducing nucleophilicity of the aniline and hence the propensity for aziridinium ion formation, (for examples, compare the compound pairs 3e/3f, 2a/2e, and 2b/2h).
To probe the structure-activity relationship and examine MGMT and MMR dependence in more detail, the results for dimeric compounds 3a-e were presented in Hammett plots, Figure 2 . The Hammett constant σ-p is a structural parameter that measures the electron donating or withdrawing effect of the substituent "X" on the aniline ring. The plot of IC50 against σ-p is informative in several respects, Figure   2A . For each cell type, the graph shows a pair of lines, the dotted line being MGMT-inactivated data (i.e. PaTrin 2 present); the difference between the solid and dotted lines shows the effect of MGMT on the cellular response. For most analogs this separation is of the same order as the error bars on the data, so in effect is zero. This is a clear demonstration that these new compounds have activity independent of MGMT function and is consistent with a mechanism of action independent of guanine-O6 alkylation (or involving a guanine-O6 adduct that cannot be repaired by MGMT). The separation between the two pairs of lines is the MMR effect which ranges from about 2-5-fold on the IC50, which is greatly reduced from the >27-fold effect measured for TMZ. p-Methyl-substituted analog 3b lies on a minimum in the graph so is optimally potent, with a modestly electron-donating substituent on the aniline ring, Figure 2A . The data for all analogues except 3e (X = OMe) lie on exponential curves (see the semi-log plot, Figure 2B ). The anomalous data for 3e are likely due to enhancement of the basicity of the aniline nitrogen lone pair leading to appreciable protonation at the pH of the experiment, and thereby a reduced propensity to act as a nucleophile in the aziridinium ionforming reaction. These data clearly demonstrate the direct effect of electron density at the aniline nitrogen in determining the in vitro activity of the compounds, so provide further evidence that the aziridinium ion mechanism occurs in cells. 
NCI60 Panel Data
Compounds 2d, and 3c-e were selected for full screening in the NCI 60 cell line panel. Mean graph data are presented in Figures S1-6 and are summarized in Table 1 . These data show that the NCEs have pharmacological activity distinct from TMZ. TMZ is essentially inactive against the panel (GI50 > 10 -4 M for 57/60 cell lines, Figure S1 ). In contrast, the new agents exhibit strong patterns of discrimination over a 2-3-log range of GI50 (Table 1 and ; this is important as it shows that the new compounds possess a degree of selectivity and are not uniformly cytotoxic against cells grown in culture. These data compare favorably with the logGI50 mean and range data for established agents CHB, MEL, CP, BCNU and CCNU; this shows there is good reason to suppose that the new compounds may have an acceptable therapeutic index and be no more systemically toxic in vivo than these other clinically useful agents. Particular sensitivity is evident in the leukemia, CNS and ovarian sub-panels. In the CNS sub-panel, the pattern of activity is similar to MTZ and CP, with particular sensitivity in the glioblastoma lines SF295 and SNB75. In the ovarian sub panel, particular sensitivity is seen in the OVACR-3 and SK-OV-3 lines. Here, in contrast to the CNS activity, the new compounds show improvement over CP (see Figure S6 ) this is a particularly interesting result given the wide clinical use of CP against ovarian adenocarcinoma and the fact that TMZ lacks clinical activity against ovarian cancer. 21 COMPARE analysis of mean graph data can be valuable in discerning molecular mechanisms of action.
Log GI50
The similarity in patterns of response is assessed by the Pearson rank correlation coefficient, P: values > 0.7 are considered highly significant, values 0.6-0.7 less so. 22, 23 Matrix COMPARE was valuable in confirming the novelty of mechanism of action of the new agents. In this method of data handling, the new compounds were compared with standard agents selected for similarities of chemical structure or predicted mechanism of action. Agents selected were other imidazotetrazines (TMZ, MTZ), nitrogen mustard cross linkers (chlorambucil CHB, melphalan MEL), nitrosoureas (1,3- Table 2 . Correlations amongst the four new imidazotetrazine compounds examined were all strong (0.92 ≤ P ≥ 0.77) and, interestingly, there was no clear discrimination between the mono-and bi-functional agents: for monofunctional 2d, 0.83 ≤ P ≥ 0.77 and in particular P = 0.79 with the equivalent p-Cl dimer 3d.
Gratifyingly, the new compounds showed only moderate correlations (0.52 ≤ P ≥ 0.38) with the established imidazotetrazines TMZ and MTZ, so are distinct as new members of this compound class. The absence of correlation with MTZ is significant as this compound, exhibits a characteristic pattern of differential activity across the panel, unlike TMZ.
The putative DNA lesion of the bifunctional agents 3 is a five-atom crosslink, related in structure to those formed by the nitrogen mustard prodrugs; however, no drugs of this class showed strong correlations 0.59 ≤ P ≥ 0.29. Notably, there was no similarity to the nitrosoureas which are also diazonium ion precursors, 0.45 ≤ P ≥ 0.05. The new compounds all showed strong correlations with dacarbazine (DTIC, highest dose = 1 µM). This observation is not easy to interpret, as this prodrug requires hepatic oxidative demethylation in order to release its active electrophile, so it is somewhat surprising that DTIC scored so highly against the new imidazotetrazines. Part of the reason for this may lie in the two relatively featureless datasets of DTIC [mean log GI50(SD) = -4.30(0.28), range = 0.99, high conc. = 10 4 M; mean log GI50(SD) = -3.66(0.548), range = 2.55, high conc. = 10 -3 M] and a shared sensitivity in the leukemia sub- All of the NCI cell lines are characterized for expression of MGMT and components of MMR. 27 Plots of protein expression vs. log GI50 were prepared to probe correlation or inverse correlation between GI50 and -16 -expression of MGMT, hMLH1 (the core MMR protein) or MSH6 (the MMR domain that recognizes O6-
For each of the compounds 2d, 3c-e, the graphs showed scatters with no connection between the protein expression levels and GI50: a result consistent with the independence of activity from MGMT and MMR found in the A2780 cell line screen. Table 3 . Selected results from NCI60 screen and COMPARE analysis using the log GI50 data as seed in the Standard Agents and Molecular Targets databases.
Further in vitro evaluation
The new compounds were further assessed in selected drug-resistant cell lines (Tables 4 and 5). HCT116 is a human colon carcinoma cell line that is deficient in both MGMT and MMR, in consequence it is insensitive to both TMZ and CP. [28] [29] [30] Both mono-and bi-functional agent families showed considerably more potent activity than TMZ and MTZ in this cell line and, in further contrast, activity was retained in the p53-deficient mutant, Table 5 . TMZ activity is known to be p53 dependent. 31 Compounds were also evaluated against an isogenic pair of SNB19 GBM cell lines competent in MMR that either expressed MGMT, SNB19(MGMT), or were negative for MGMT, SNB19(vector). This pair of cell lines highlights the improvements the new bi-functional agents offer over TMZ. The MGMTproficient line being remarkably insensitive to TMZ (IC50 is unattainable) and the new bi-functional agents showing equivalent activity against the two lines (IC50 6-12 µM) with increased potency against both SNB19(vector) and SNB19 (MGMT). A2058 is an aggressive melanoma line that is TMZ-sensitive and even so, the new bi-functional agents show a 10-fold increase in potency. 
A2058
Discussion and Conclusions
The aims of generating new imidazotetrazine prodrugs with activity independent of MGMT and MMR have been achieved through a rationally-designed switch in molecular mechanism. This complements other work, where alternative GO6-lesion dependent strategies have been pursued. 29 Two new families of mono-and bi-functional 3-anilinoethyl imidazotetrazines have been prepared.
These were designed to shift the mechanism of action from dependence on GO6-DNA modification to GN7-modification. This was achieved through trapping the diazonium electrophile released on hydrolysis of the imidazotetrazine prodrug as an aziridinium ion. The mono-functional agent 2b is efficiently converted to an aziridinium ion (Scheme 2) and 2b and 3b are both DNA GN7-alkylators. 15 It is proposed, on the basis of analogy with reactive intermediates generated by nitrogen mustard and similar prodrugs, that biological activity is likely associated with this lesion. However it is not yet possible to distinguish definitively between a mechanism of action deriving from GN7-adduct formation and one proceeding from GO6-adducts that are resistant to MGMT-mediated repair.
Screening in A2780 and A2780-cp70 cell lines showed that the new compounds are more potent than TMZ. The mono-functional agents are approximately equipotent with MTZ and the bi-functional agents more active. This activity is independent of MGMT activity as determined by use of the MGMT inactivator PaTrin2. Dependence of the IC50 on MMR is greatly reduced from approximately 30-fold for TMZ to 2-5-fold for the new bi-functional agents. The Hammett plot, Figure 2 , for the bi-functional agents demonstrates the critical rôle of the para-substituent in directing the reactivity and bioactivity of the compounds, consistent with the aziridinium ion mechanism occurring in vitro and corroborating the design principles. The data identified the p-toluidine derivative 3b as the optimal analog for MGMT and MMR independence and potency.
In the NCI60 screen, the new agents were not uniformly cytotoxic and showed distinct and individual patterns of response over a near 3-log range of GI50. The patterns of biological response to the new agents were distinct from standard agents drawn from the imidazotetrazine, nitrogen mustard and nitrosourea families which, by chemical consideration, may be predicted to share similar mechanisms of action. For all compounds evaluated in the full 60 cell line screen, there was neither correlation with MLH1 or MSH6, nor inverse correlation with MGMT protein expression levels.
Correlations in the Molecular Targets database suggest there may be a specific molecular mechanism that accounts for the sensitivity of the leukemia sub-panel to the new agents and, moreover, that activity could be linked to RAS family oncogenes.
Collectively, the in vitro data show that the initial aims of improved potency and MGMT and MMR independence have been achieved. The switch of chemical mechanism has resulted in new agents that are distinct from existing imidazotetrazines, nitrogen mustards and nitrosoureas. This implies that an increased diversity of tumor types may now be able to respond to drugs of the imidazotetrazine class.
NCI60 panel data identified CP-resistant ovarian carcinoma cell lines as responsive to the new agents.
Chemosensitivity in selected drug-resistant colon carcinoma and glioma cell lines (HCT116 and SNB19) showed that there is activity against TMZ-and CP-resistant tumor lines of these types, and -21 - moreover, that the HCT116 response is independent of p53 status. The ability of cells to repair damage by the new agents is linked to the ATR and FANC pathways for the bi-functional and ATM and FANC pathways for mono-functional agents. 32 Mutation in one of these genes would hypersensitize a tumour to these new agents.
Overall these findings validate our understanding of the underlying chemistry of imidazotetrazine prodrugs. The members of our compound library are distinctive new agents, worthy of further development and application against a more diverse range of tumor types than TMZ.
Experimental
Synthesis
Reagents were purchased from Sigma-Aldrich, Alfa Aesar and Fluka, solvents from Fisher Compounds 2b and 3b were prepared as described in reference 15. 
Methyl 3-((4-chlorophenyl)(methyl)amino)propanoate 12d
Prepared according to General Method A. Ester 12d was obtained as a yellow oil (9.1 g, 54%). 
Methyl 3-(tert-butoxycarbonyl-(4-chlorophenyl)amino)propanoate 12f
Ester 12g (2.27 g, 10.6 mmol) was mixed with di-tert-butyl carbonate ( 34, 35 General Method B: Preparation of monohydrazides. -25 - Ester 12g (3.7 g, 11.8 mmol, 1 eq) was mixed with hydrazine hydrate (5.9 g, 118 mmol, 10 eq) in propan-2-ol (10 mL) for 48h at RT. The volatiles were removed with evaporation to leave hydrazide 13g as colorless oil (3.5 g, 95%). 1 
3-(4-Chlorophenylamino)propanehydrazide 13g
3-(Methyl(phenyl)amino)propanehydrazide 13a
Prepared according to General Method B. Hydrazide 13a was obtained as a colorless oil (12.7 g, 98%). 1 
3-((4-Fluorophenyl)(methyl)amino)propanehydrazide 13c
Prepared according to General Method B. Hydrazide 13c was obtained as a yellow oil ( 
3-((4-Chlorophenyl)(methyl)amino)propanehydrazide 13d
Prepared according to General Method B. Hydrazide 13d was obtained as white solid (4.0 g, 
3-((4-Methoxyphenyl)(methyl)amino)propanehydrazide 13e
Prepared according to General Method B. Hydrazide 13e was obtained as an oil which crystallized upon standing (4.5 g, 95%): 1 
tert-Butyl-4-chlorophenyl(3-hydrazinyl-3-oxopropyl)carbamate 13f
Prepared according to General Method B. Hydrazide 13f was obtained as a colorless oil (3.5 g, 95%). 1 -3,4-dihydroimidazo[5,1-d][1,2,3,5 ]tetrazine-8-
3-(2-(4-Chlorophenylamino)ethyl)-4-oxo
carboxamide 2g
General Method C: Preparation of mono-imidazotetrazines Hydrazide 13g (1.0 g, 4. 68 mmol) was dissolved in dichloromethane (20 mL) . Water (20 mL) was added followed by HCl (2.5 mL, 37%) . The mixture was cooled in an ice/CaCl 2 bath and a solution of NaNO 2 (0.39 g, 56.2 mmol, 1.2 eq) in water (10 mL) was added with strong agitation at below -5 °C. The ice bath was removed and dichloromethane (20 mL -3,4-dihydroimidazo[5,1-d][1,2,3,5 Butyl 2-(8-carbamoyl-4-oxoimidazo[5,1-d][1,2,3 N-(4-Fluorophenyl) -N-methylamino)ethyl isocyanate 15c -31 - The anhydrous DCM solution of azide 14c was stirred under nitrogen at RT overnight.
3-(2-(Methyl(phenyl)amino)ethyl)-4-oxo
tert-
2-(
Isocyanate 15c formation was confirmed by IR and 1 H NMR. The DCM was evaporated under reduced pressure at low temperature (an ice bath was used to lower the temperature). The isocyanate was collected as a yellow oil (0.2 g, 77%). 1 
2-[(4-Nitrophenyl)methylamino]ethylisocyanate 15e
The anhydrous DCM solution of the crude azide 14e was stirred under nitrogen at RT overnight. 
3,3'-(4-Chlorophenylazanediyl)dipropanehydrazide 10d
General Method E: Preparation of bis-hydrazides Diester 8d (19 g, 63.4 mmol) was mixed with hydrazine hydrate ( 
3,3'-(4-Fluorophenylazanediyl)dipropanehydrazide 10c
Prepared according to General Method E. Hydrazide 10c was obtained as a white solid (0.63 g, 
3,3'-(2,2'-(4-Chlorophenylazanediyl)bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1d][1,2,3,5]tetrazine-8-carboxamide) 3d
General Method F: Preparation of bis-imidazotetrazines Hydrazide 10d (1.0 g, 3.18 mmol, 1 eq) was dissolved in dichloromethane (10 mL). Water (10 mL) was added followed by HCl (2.5 mL, 37 %) . The mixture was cooled in an ice/CaCl 2 bath and a solution of NaNO 2 (0.57 g, 8.26 mmol, 2.6 eq) in water (10 mL) was added with strong agitation below 5 °C. After the addition, the reaction was allowed to reach RT and stirred overnight. The organic layer was separated, dried over MgSO 4 and evaporated to give the azide 11d as a crude oil, identified by IR. The oil was diluted with toluene (100 mL) and heated under reflux for 2 h under N 2 . The volatile components were removed to give the crude isocyanate 9d as an oil. Diethylether (150 mL) was added and the mixture heated with strong agitation. The hot solution was decanted leaving a residue of oily impurities behind. The ether was evaporated to leave pure isocyanate as pale yellow oil (IR ν max 2260s). The isocyanate (0.29g, 1.03 mmol) was mixed with diazo-IC 5 (0. 
